Surgical Tissue Flap to Bypass the Blood Brain Barrier in Glioblastoma
Part of paid clinical trials in New York, New York.
- Sponsor
- Northwell Health
- Study ID
- NCT05954858
- Status
- Recruiting
Conditions
- Brain Cancer
- GBM
- Glioblastoma
- Glioblastoma Multiforme
- Glioblastoma Multiforme, Adult
- Glioma, Malignant
- High Grade Glioma
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Tissue autograft of pedicled temporoparietal fascial (TPF) or pericranial flap to bypass the blood brain barrier (BBB) — PROCEDURESurgical tissue autograft of pedicled temporoparietal fascial (TPF) or pericranial flap into the resection cavity of newly diagnosed glioblastoma multiforme (GBM) patients.
Study Details
This single center, single arm, open-label, phase 2 study will assess the safety and efficacy of a pedicled temporoparietal fascial (TPF) or pericranial flap into the resection cavity of newly diagnosed glioblastoma multifome (GBM) patients. The objective of the Phase 2 study is to demonstrate that this surgical technique is safe and effective in a human cohort of patients with resected newly diagnosed AA or GBM and may improve progression-free survival (PFS) and overall survival (OS).
Key Dates
- Start date
- Jun 29, 2023
- Status verified
- May 2026
- Primary completion
- Jun 30, 2028
- Completion
- Jun 30, 2029
Study Design
- Enrollment
- 32 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Surgical tissue autograft: TPF flap/pericranial flapUse of a pedicled autologous piece of tissue called the temporoparietal fascial (TPF) flap or pericranial flap into the resection cavity of newly diagnosed glioblastoma multiforme (GBM) patients
Primary Outcome Measure
Progression Free Survival (PFS) [ Time Frame: 6 months ]
Central Contacts
- John Boockvar, MD212-434-3900
- Tamika Wong, MPH212-434-4836
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Lenox Hill Brain Tumor Center | New York | New York | 10075 | David Langer, MD (SUB_INVESTIGATOR) Netanel Ben-Shalom, MD (SUB_INVESTIGATOR) Randy D'Amico, MD (SUB_INVESTIGATOR) Deborah Gruber, MD (SUB_INVESTIGATOR) Avraham Zlochower, MD (SUB_INVESTIGATOR) Vadim Zhigin, PA (SUB_INVESTIGATOR) Olivia Albers, NP (SUB_INVESTIGATOR) Amy McKewon, NP (SUB_INVESTIGATOR) Tamika Wong, MPH (SUB_INVESTIGATOR) |
Find similar trials in New York, NY
By condition
By specialty
By research site
Related Studies
- Magnetic Resonance (MR) Imaging to Determine High Risk Areas in Patients With Malignant Gliomas and to Design Potential Radiation Plans and to Examine Metabolite Changes in Gliomas and Other Solid TumorsRecruiting · Memorial Sloan Kettering Cancer Center · New York, New York
- Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AAPHASE1/PHASE2 · Recruiting · Northwell Health · New York, New York
- Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated GliomaPHASE1/PHASE2 · Recruiting · Neonc Technologies, Inc. · Los Angeles, California
- Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOAPHASE2 · Recruiting · Northwell Health · New York, New York